Physician profile
John Giannakis
NPI 1063472470
$4,227.46
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $301 · 2021: $905 · 2022: $1,048 · 2023: $988 · 2024: $39.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026 · Education: $1.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.93 |
| Education | $1.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.33 | 2019-2023 | |
| Janssen Biotech, INC. | $504.35 | 2019-2023 | |
| Pfizer INC. | $376.83 | 2019-2023 | |
| Astellas Pharma US INC | $353.53 | 2019-2023 | Myrbetriq |
| Coloplast Corp | $337.94 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $277.90 | 2021-2023 | Prolaris, Bracanalysis Cdx, Myrisk |
| Endo Pharmaceuticals INC. | $202.89 | 2019-2024 | Xiaflex, Aveed |
| Axonics, INC. | $195.19 | 2020-2023 | Axonics |
| Allergan, INC. | $153.58 | 2019-2022 | |
| Antares Pharma, INC. | $151.35 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Urogen Pharma, INC. | $131.52 | 2021-2023 | Jelmyto |
| Boston Scientific Corporation | $99.67 | 2019-2023 | Spaceoar Vue System - 10ml |
| Sumitomo Pharma America, INC. | $98.53 | 2023-2024 | Gemtesa |
| C. R. Bard, INC. & Subsidiaries | $97.04 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $73.56 | 2021-2023 | Oxlumo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $72.47 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.40 | 2019-2022 | |
| Aytu Biopharma, INC. | $64.19 | 2019 | |
| Halozyme INC | $56.49 | 2023 | |
| Hollister Incorporated | $54.11 | 2022-2023 | Vapro Pocket |
| Teleflex LLC | $48.50 | 2019-2021 | |
| Medtronic, INC. | $47.91 | 2022-2023 | Interstim |
| Therapeuticsmd, INC. | $44.03 | 2019-2020 | |
| Myovant Sciences INC. | $26.74 | 2022 | |
| Procept Biorobotics Corporation | $26.52 | 2022 | |
| Agiliti Surgical, INC. | $23.66 | 2019 | |
| Telix Pharmaceuticals | $23.61 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $23.00 | 2019 | |
| Convatec INC. | $22.34 | 2022 | |
| Genzyme Corporation | $20.76 | 2022 | |
| Dendreon Pharmaceuticals LLC | $16.37 | 2019 | |
| Renovia INC | $12.36 | 2019 | |
| Clarus Therapeutics INC. | $8.69 | 2021 | |
| Travere Therapeutics, INC. | $1.10 | 2023 | Thiola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Giannakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.